Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage breakthrough neuropsychiatry company focused on developing innovative mental healthcare treatments, has announced its participation in the Lytham Partners 2025 Investor Healthcare Summit.

The company's CEO, Doug Drysdale, will engage in a fireside chat during the virtual event on January 13, 2025, at 11:30 a.m. ET. The session will be available through a live webcast, and an archived version will be accessible on the company's investor relations website under the Events & Presentations section.

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Lytham Partners 2025 Investor Healthcare Summit taking place virtually on January 13, 2025.

The fireside chat will be webcast live on Monday, January 13, 2025, at 11:30 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of Major Depressive Disorder and CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule in a Phase 2 study for Generalized Anxiety Disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250109613937/en/

Investor & Media Contact:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

irteam@cybin.com – or – media@cybin.com

Source: Cybin Inc.

FAQ

When is Cybin's (CYBN) fireside chat at the Lytham Partners 2025 Healthcare Summit?

Cybin's fireside chat is scheduled for Monday, January 13, 2025, at 11:30 a.m. ET during the Lytham Partners 2025 Investor Healthcare Summit.

How can investors watch Cybin's (CYBN) presentation at the Lytham Partners Summit?

Investors can watch the fireside chat through a live webcast, and the archived version will be available on Cybin's investor relations website under the Events & Presentations page.

Is the Lytham Partners 2025 Healthcare Summit where Cybin (CYBN) is presenting an in-person event?

No, the Lytham Partners 2025 Investor Healthcare Summit is being held virtually.

What type of company is Cybin (CYBN) presenting as at the Lytham Partners Summit?

Cybin is presenting as a clinical-stage breakthrough neuropsychiatry company focused on developing new and innovative next-generation mental healthcare treatment options.